Myocet is a non-pegylated liposomal formulation of the chemotherapy drug doxorubicin. It is designed to reduce the cardiotoxicity commonly associated with standard doxorubicin treatment. Myocet is used primarily in combination with other chemotherapy agents to treat various types of cancer, most notably metastatic breast cancer.
